Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04678063
Other study ID # ALY-003
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 10, 2017
Est. completion date July 11, 2017

Study information

Verified date December 2020
Source Alyatec
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double blind, cross-over study designed to determine the concentration of airborne cat allergen inducing bronchial response in asthmatic subjects allergic to cat, during allergen exposures in the Alyatec environmental exposure chamber (EEC). The study was also designed to validate the specificity of the asthmatic reaction induced by exposure to airborne cat allergen in Alyatec EEC.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date July 11, 2017
Est. primary completion date June 15, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Subjects having signed the informed consent - Subjects affiliated to a social security scheme - Non-specific bronchial hyperreactivity (HRBNS) assessed by a positive methacholine test - FEV1 value > 70% of theoretical FEV1 value - Asthma Control Test (ACT) = 20/25 in 4 weeks prior to EEC exposure - Women of childbearing potential should have a negative pregnancy test throughout the study period with effective contraception. Group A: - Cat allergic asthma (GINA 1, 2) associated with rhinitis and / or conjunctivitis symptoms triggered during an exposure to a cat. - Positive skin prick-test to cat allergen extract (wheal diameter >3 mm compared to the negative control) Specific immunoglobulin E (IgE) for cat allergen > 0.7 kU/L Group B: - Mild allergic asthma (GINA 1 or 2) not sensitized to cat allergen with associated rhinitis and/or conjunctivitis. - Negative skin prick-test and specific IgE for cat allergen - Positive skin prick-test and specific IgE for another allergen. Exclusion Criteria: - Uncontrolled asthma, ACT asthma control questionnaire less than 20, in the last 4 weeks - Uncontrolled asthma 2 weeks after interruption of LABA - Long-term treatment by LABA, within 2 weeks prior to inclusion - Existence of a severe obstructive syndrome with FEV1 <70% of the theoretical value - Obstruction triggered by spirometric evaluations - Hospitalization for asthma or exacerbation in the last 4 weeks - Subjects treated with oral corticosteroids in the 4 weeks prior to inclusion in the study - History of severe acute asthma requiring hospitalization in intensive care or intubation - Subjects treated with biotherapy in the 4 months prior to inclusion in the study - Presence of a cat at home, or daily exposure to cat allergens - Desensitization to cat allergens in the last 6 months - Active tobacco: plus 10 cigarettes / day or tobacco history plus 10 PA

Study Design


Intervention

Other:
Exposure to Placebo
Patients are exposed to placebo in the EEC
Exposure to dose A and dose B of cat allergen
Patients are exposed to dose A and B for successive exposures in the EEC
Exposure to a single dose of cat allergen
Patients are exposed to a single dose of cat allergen in the EEC according to the dose selected to achieve the main objective (dose A or B)

Locations

Country Name City State
France Alyatec Strasbourg Grand Est

Sponsors (1)

Lead Sponsor Collaborator
Alyatec

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the concentration of cat allergen (in ng/m3 of Der p1) necessary to induce a bronchial response in at least 60% of asthmatic subjects allergic to cat. The bronchial response is evaluated by measuring FEV1 value.
Early asthmatic response (EAR) occurs when a 20 percent drop in FEV1 is detected during the exposure compared to the pre-exposure FEV1.
Late bronchial response (LAR) occurs when a 15 percent drop in FEV1 or 20 percent drop in peak flow is detected 1 to 6h after the EAR.
10 hours: 4 hours of exposure in EEC then 6 hours post-exposure
Secondary Evaluate the safety of allergenic exposure in EEC Safety is assessed with an asthma symptom self-report questionnaire performed during the 4h exposure and for 24h after the end of the exposure.
The score was obtained from the sum of all four individual symptom scores (chest tightness, cough, wheezing and dyspnea) with a total possible score ranging from 0 (no symptoms) to 16 (maximum symptom intensity).
28 hours: 4 hours of exposure in EEC then 24 hours post-exposure
Secondary Evaluate the allergen concentration in the EEC The measurement of allergen concentration is performed with several sensors positioned in the chamber. 4 hours exposure in EEC
Secondary Evaluate the specificity of the bronchial response The specificity of the bronchial response is assessed with the exposure to cat allergen in the EEC of asthmatic allergic subjects non sensitized to cat. 4 hours exposure in EEC
Secondary Evaluate the effect of the exposure on rhinitis symptoms The effect of the exposure on the rhinitis response is assessed with Total Nasal Symptom Score (TNSS).
The TNSS was obtained from the sum of all four individual symptom scores, with a total possible score ranging from 0 (no symptoms) to 12 (maximum symptom intensity).
28 hours: 4 hours of exposure in EEC then 24 hours post-exposure
Secondary Evaluate the effect of the exposure on conjunctivitis symptoms The effect of the exposure on the conjunctivitis response is assessed with Total Ocular Symptom Score (TOSS).
The TOSS was obtained from the sum of all four individual symptom scores, with a total possible score ranging from 0 (no symptoms) to 12 (maximum symptom intensity).
28 hours: 4 hours of exposure in EEC then 24 hours post-exposure
See also
  Status Clinical Trial Phase
Terminated NCT02032056 - Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period N/A
Completed NCT01842711 - Cumulative Irritation Patch Test N/A
Completed NCT01633840 - New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges N/A
Completed NCT00554983 - Efficacy and Safety From a Recombinant Folding Variant of Bet v 1 Phase 3
Completed NCT00997971 - Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein Phase 3
Completed NCT00331929 - Respiratory Health Study of Children in Kiryat Tivon N/A
Completed NCT00220753 - Air Cleaners for Children and Adolescents With Asthma and Dog Allergy N/A
Completed NCT00232518 - Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis N/A
Completed NCT04126096 - Negative Predictive Value and NIC of Beta-Lactam Antibiotics. N/A
Completed NCT04046731 - Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation N/A
Completed NCT04004351 - Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
Not yet recruiting NCT05997784 - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Completed NCT04418999 - Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus Early Phase 1
Completed NCT04186949 - Early Origins of Allergy and Asthma
Completed NCT02127801 - Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants Phase 1
Enrolling by invitation NCT05011071 - The Alberta BLOOM Premature Child Study
Not yet recruiting NCT06330974 - Allergy, Asthma, and Atopic Eczema in Finland
Completed NCT02306473 - The Leaky Lung Test Early Phase 1
Completed NCT02596321 - A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma Phase 3
Terminated NCT02601690 - Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America

External Links